GLAUKOS CorpGKOS财报
NYSE · 医疗保健 · 外科及医疗仪器和设备
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| BlackRock, Inc. | 16.20% | 7.9M | — | 2024-01-22 |
| FMR LLC | 12.06% | 5.9M | ▲ +1.83pp | 2024-02-09 |
| The Vanguard Group | 10.73% | 5.2M | — | 2024-02-13 |
| Thomas W. Burns | 5.08% | 2.6M | — | 2024-02-13 |
| NOS. OF ABOVE PERSONS | 2.97% | 1.6M | ▼ -2.56pp | 2024-11-14 |
| Wellington Management Group LLP | 2.75% | 1.3M | — | 2024-01-10 |
内部人交易
Net 90d: −$2.60M · buys $0 / sells $2.60M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-10 | Tomas Navratil | CHIEF DEVELOPMENT OFFICER | Sell (open market) | 1.2K | $116.72 | $144.4K |
| 2026-04-10 | Tomas Navratil | CHIEF DEVELOPMENT OFFICER | Sell (open market) | 210 | $117.45 | $24.7K |
| 2026-04-10 | Tomas Navratil | CHIEF DEVELOPMENT OFFICER | Sell (open market) | 614 | $119.35 | $73.3K |
| 2026-04-10 | Tomas Navratil | CHIEF DEVELOPMENT OFFICER | Sell (open market) | 32 | $120.23 | $3.8K |
| 2026-04-01 | Burns Thomas William | CHAIRMAN & CEO | Gift | 180.3K | $0.00 | $0 |
| 2026-04-01 | Burns Thomas William | CHAIRMAN & CEO | Gift | 180.3K | $0.00 | $0 |
| 2026-03-25 | Burns Thomas William | CHAIRMAN & CEO | Grant | 9.4K | $0.00 | $0 |
| 2026-03-25 | Burns Thomas William | CHAIRMAN & CEO | Grant | 14.2K | $0.00 | $0 |
| 2026-03-25 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Sell (open market) | 2.5K | $106.46 | $267.3K |
| 2026-03-25 | Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Grant | 3.3K | $0.00 | $0 |
1–10 of 31
第 1 页 / 共 4 页